Skip to Content
Merck
CN
  • Novel Two MRT Cell Lines Established from Multiple Sites of a Synchronous MRT Patient.

Novel Two MRT Cell Lines Established from Multiple Sites of a Synchronous MRT Patient.

Anticancer research (2020-10-29)
Yasumichi Kuwahara, Tomoko Iehara, Eisuke Ichise, Yoshiki Katsumi, Kazutaka Ouchi, Kunihiko Tsuchiya, Mitsuru Miyachi, Eiichi Konishi, Hiroyasu Sasajima, Satoaki Nakamura, Shigehisa Fumino, Tatsuro Tajiri, Pascal D Johann, Michael C FrÜhwald, Tatsushi Yoshida, Tsukasa Okuda, Hajime Hosoi
ABSTRACT

Malignant rhabdoid tumor (MRT) is a rare, aggressive neoplasm found in young children, caused by inactivation of a single gene, SNF5 (INI1, SMARCB1). MRT cases with multifocal tumors at diagnosis are categorized as synchronous MRT, often with a germline mutation of SNF5. The aim of this study was to establish new models useful in clarifying the biological basis of synchronous MRT. We established two novel MRT cell lines, designated as KP-MRT-KS and KP-MRT-KSa, derived from different lesions and at a different time from a synchronous multifocal 7-month-old female MRT patient. Both cells showed typical morphology of MRT, with a compound genomic mutation in exons 2 and 5 of the SNF5 gene. The exon 2 mutation was found in the germline. These cell lines could serve as powerful tools for unveiling the molecular mechanism of refractory synchronous MRT.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-Actin, α-Smooth Muscle, clone 1A4, ascites fluid